Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison.
The true severity of infection due to COVID-19 is under-represented because it is based on only those who are tested. Although nucleic acid amplifications tests (NAAT) are the gold standard for COVID-19 diagnostic testing, serological assays provide better population-level SARS-CoV-2 prevalence estimates. Implementing large sero-surveys present several logistical challenges within Canada due its unique geography including rural and remote communities. Dried blood spot (DBS) sampling is a practical solution but comparative performance data on SARS-CoV-2 serological tests using DBS is currently lacking. Here we present test performance data from a well-characterized SARS-CoV-2 DBS panel sent to laboratories across Canada representing 10 commercial and 2 in-house developed tests for SARS-CoV-2 antibodies. Three commercial assays identified all positive and negative DBS correctly corresponding to a sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI = 72.2, 100). Two in-house assays also performed equally well. In contrast, several commercial assays could not achieve a sensitivity greater than 40% or a negative predictive value greater than 60%. Our findings represent the foundation for future validation studies on DBS specimens that will play a central role in strengthening Canada's public health policy in response to COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
PLoS ONE - 16(2021), 12, p e0261003 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
François Cholette [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1371/journal.pone.0261003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ003080978 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ003080978 | ||
| 003 | DE-627 | ||
| 005 | 20230309173125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0261003 |2 doi | |
| 035 | |a (DE-627)DOAJ003080978 | ||
| 035 | |a (DE-599)DOAJ643763f401f642028ffbe4945d1b28da | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a François Cholette |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The true severity of infection due to COVID-19 is under-represented because it is based on only those who are tested. Although nucleic acid amplifications tests (NAAT) are the gold standard for COVID-19 diagnostic testing, serological assays provide better population-level SARS-CoV-2 prevalence estimates. Implementing large sero-surveys present several logistical challenges within Canada due its unique geography including rural and remote communities. Dried blood spot (DBS) sampling is a practical solution but comparative performance data on SARS-CoV-2 serological tests using DBS is currently lacking. Here we present test performance data from a well-characterized SARS-CoV-2 DBS panel sent to laboratories across Canada representing 10 commercial and 2 in-house developed tests for SARS-CoV-2 antibodies. Three commercial assays identified all positive and negative DBS correctly corresponding to a sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI = 72.2, 100). Two in-house assays also performed equally well. In contrast, several commercial assays could not achieve a sensitivity greater than 40% or a negative predictive value greater than 60%. Our findings represent the foundation for future validation studies on DBS specimens that will play a central role in strengthening Canada's public health policy in response to COVID-19. | ||
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Christine Mesa |e verfasserin |4 aut | |
| 700 | 0 | |a Angela Harris |e verfasserin |4 aut | |
| 700 | 0 | |a Hannah Ellis |e verfasserin |4 aut | |
| 700 | 0 | |a Karla Cachero |e verfasserin |4 aut | |
| 700 | 0 | |a Philip Lacap |e verfasserin |4 aut | |
| 700 | 0 | |a Yannick Galipeau |e verfasserin |4 aut | |
| 700 | 0 | |a Marc-André Langlois |e verfasserin |4 aut | |
| 700 | 0 | |a Anne-Claude Gingras |e verfasserin |4 aut | |
| 700 | 0 | |a Cedric P Yansouni |e verfasserin |4 aut | |
| 700 | 0 | |a Jesse Papenburg |e verfasserin |4 aut | |
| 700 | 0 | |a Matthew P Cheng |e verfasserin |4 aut | |
| 700 | 0 | |a Pranesh Chakraborty |e verfasserin |4 aut | |
| 700 | 0 | |a Derek R Stein |e verfasserin |4 aut | |
| 700 | 0 | |a Paul Van Caeseele |e verfasserin |4 aut | |
| 700 | 0 | |a Sofia Bartlett |e verfasserin |4 aut | |
| 700 | 0 | |a Mel Krajden |e verfasserin |4 aut | |
| 700 | 0 | |a David Goldfarb |e verfasserin |4 aut | |
| 700 | 0 | |a Allison McGeer |e verfasserin |4 aut | |
| 700 | 0 | |a Carla Osiowy |e verfasserin |4 aut | |
| 700 | 0 | |a Catherine Hankins |e verfasserin |4 aut | |
| 700 | 0 | |a Bruce Mazer |e verfasserin |4 aut | |
| 700 | 0 | |a Michael Drebot |e verfasserin |4 aut | |
| 700 | 0 | |a John Kim |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Immunity Task Force (CITF) working group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t PLoS ONE |d Public Library of Science (PLoS), 2007 |g 16(2021), 12, p e0261003 |w (DE-627)DOAJ000113018 |x 19326203 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:12, p e0261003 |
| 856 | 4 | 0 | |u https://doi.org/10.1371/journal.pone.0261003 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/643763f401f642028ffbe4945d1b28da |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1371/journal.pone.0261003 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1932-6203 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |e 12, p e0261003 | ||